Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan

CONCLUSIONS: This study suggests that Pola + R-CHP is a cost-effective treatment for previously untreated DLBCL in Japan under the public health insurance system.PMID:37656225 | DOI:10.1080/13696998.2023.2254162

Source: Journal of Medical Economics - September 1, 2023 Category: Health Management Authors: Takashi Mizuoka Hiroyuki Sakamaki Shigeo Fuji Shota Saito Tatsunori Murata Shinya Ohno Naoki Inubashiri Tomoha Oshima Kazuhito Yamamoto Source Type: research